Trial · NCT05052801
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801, Phase 3, Completed, Amgen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression. Trials, record NCT05052801. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05052801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- NCT number
- NCT05052801
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 547 participants, actual
- Lead sponsor
- Amgen
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Bemarituzumab, mFOLFOX6, Placebo
- First posted
- 2021-09-22
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | Up to approximately 3.5 years | Overall survival in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Progression-free Survival (PFS) | Up to approximately 3.5 years | PFS in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Objective Response Rate (ORR) | Up to approximately 3.5 years | ORR in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Number of Participants who Experience a Treatment-emergent Adverse Event (TEAE) | Up to approximately 3.5 years | Any clinically significant changes in vital signs, visual acuity, and clinical laboratory tests after first dose will be recorded as TEAEs. |
| Secondary | Overall Survival | Up to approximately 3.5 years | Overall survival in all randomized participants |
| Secondary | Progression-free Survival (PFS) | Up to approximately 3.5 years | PFS in all randomized participants |
| Secondary | Objective Response Rate (ORR) | Up to approximately 3.5 years | ORR in all randomized participants |
| Secondary | Duration of Response (DOR) | Up to approximately 3.5 years | DOR in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Disease Control Rate | Up to approximately 3.5 years | Disease Control Rate in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
| Secondary | Mean Subjective Score in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) | Up to approximately 3.5 years | Measured in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05052801
GET https://conductscience.org/api/trials/v1/NCT05052801/registered?page=2